Trovagene Inc. (TROV) Stock Price Down 2.7%
Shares of Trovagene Inc. (NASDAQ:TROV) traded down 2.7% during mid-day trading on Friday . The stock traded as low as $5.48 and last traded at $5.49, with a volume of 163,092 shares traded. The stock had previously closed at $5.64.
Several analysts have recently issued reports on the stock. Cantor Fitzgerald raised shares of Trovagene from a “hold” rating to a “buy” rating and increased their price target for the stock from $5.00 to $7.00 in a research report on Monday, August 8th. Piper Jaffray Cos. set a $4.00 price target on shares of Trovagene and gave the stock a “hold” rating in a research report on Friday, August 5th. Maxim Group increased their price target on shares of Trovagene from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research raised shares of Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, Leerink Swann restated a “hold” rating on shares of Trovagene in a research note on Thursday, May 12th. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $7.13.
The company’s market cap is $165.81 million. The company’s 50-day moving average is $5.24 and its 200 day moving average is $4.96.
Trovagene (NASDAQ:TROV) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.03. Equities research analysts anticipate that Trovagene Inc. will post ($1.33) EPS for the current fiscal year.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.